Follicular epithelial dysplasia (FED) is described as Hashimoto thyroiditis-related atypia and is thought to be a possible precancerous lesion. Dysplasia as an interface between normal state and carcinoma is described in a wide range of diseases and carcinogenesis chains. On the other hand, inflammation-related atypia and cancerogenesis is also widely studied. In this study, we retrospectively analyzed 91 specimens of thyroid gland surgical resections with FED during a 10-year-period at the university hospital pathology department. The study population consisted of 68 females and 15 males aged between 22 and 86 years. The preoperative cytology diagnoses had mainly been in the indeterminate categories with prevailing AUS/FLUS results in the FED-only group (p = 0.005) and suspicious for malignancy and malignant in the group with FED plus adjacent malignancy. The decision for surgery was malignancy related in 48.2% of the cases. The lesions were sized 0.1-3.5 mm and multifocal in 45.1% of the cases. Immunohistochemically, the atypical cells were cyclin D1-positive in 67.5%, galectin-3 in 72.7%, CK19 in 85.7%, and HBME-1 in 87.0% of cases. In conclusion, FED is suggested to be a pathogenetic link between inflammation-related atypia and papillary carcinoma and thus a premalignant precursor of papillary carcinoma in HT as 36.1% of the specimens contained also papillary carcinoma in the present study. Both histopathological nuclear features and the immunoprofile of FED are widely shared with that of papillary carcinoma.

Department of Biology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Otorhinolaryngology and Head and Neck Surgery 1st Faculty of Medicine University Hospital Motol Charles University Prague Czech Republic

Faculty of Medicine and Health Technology Tampere University Tampere Finland

Fimlab Laboratories Tampere Finland

Pathology Department Seinäjoki Central Hospital Seinäjoki Finland

Zobrazit více v PubMed

Nikiforov YE, Biddinger PW, Thompson LDR (2020) Chronic Lymphocytic Thyroiditis (Hashimoto or Autoimmune Thyroiditis). In: Nikiforov YE, Biddinger PW, Thompson LDR (eds) Diagnostic Pathology and Molecular Genetics of the Thyroid: A Comprehensive Guide for Practicing Thyroid Pathology. Wolters Kluwer N.V., Alphen aan den Rijn, the Netherlands, pp 60–71

Pusztaszeri MP, Faquin WC, Sadow PM. Tumor-Associated Inflammatory Cells in Thyroid Carcinomas. Surg Pathol Clin. 2014;7(4):501–514. doi: 10.1016/j.path.2014.08.006. PubMed DOI

Galdiero MR, Varricchi G, Marone G. The immune network in thyroid cancer. Oncoimmunology. 2016;5(6):e1168556. doi: 10.1080/2162402X.2016.1168556. PubMed DOI PMC

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013. PubMed DOI

DeNardo DG, Andreu P, Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 2010;29(2):309–316. doi: 10.1007/s10555-010-9223-6. PubMed DOI PMC

Guarino V, Castellone MD, Avilla E, Melillo RM. Thyroid cancer and inflammation. Mol Cell Endocrinol. 2010;321(1):94–102. doi: 10.1016/j.mce.2009.10.003. PubMed DOI

Ehlers M, Schott M. Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked? Trends Endocrinol Metab. 2014;25(12):656–664. doi: 10.1016/j.tem.2014.09.001. PubMed DOI

Matkowskyj KA, Chen ZE, Rao MS, Yang GY. Dysplastic lesions in inflammatory bowel disease: molecular pathogenesis to morphology. Arch Pathol Lab Med. 2013;137(3):338–350. doi: 10.5858/arpa.2012-0086-RA. PubMed DOI

Kumar V, Abbas AK, Aster JC (2020) Neoplasia. In: Kumar V, Abbas AK, Aster JC (eds) Robbins & Cotran Pathologic Basis of Disease. Elsevier Health Sciences, Philadelphia, USA, pp 267–338

Arif S, Blanes A, Diaz-Cano SJ. Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology. 2002;41(4):357–362. doi: 10.1046/j.1365-2559.2002.01467.x. PubMed DOI

Berho M, Suster S (1995) Clear nuclear changes in Hashimoto's thyroiditis. A clinicopathologic study of 12 cases. Ann Clin Lab Sci 25 (6):513–521 PubMed

Doganay L, Puyan FO, Oz F, Ergul Z, Bilgi S, Ekuklu G. Regenerative hyperplasia of follicular epithelium in chronic lymphocytic thyroiditis. Appl Immunohistochem Mol Morphol. 2005;13(4):353–357. PubMed

Gasbarri A, Sciacchitano S, Marasco A, Papotti M, Di Napoli A, Marzullo A, Yushkov P, Ruco L, Bartolazzi A. Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis. Br J Cancer. 2004;91(6):1096–1104. doi: 10.1038/sj.bjc.6602097. PubMed DOI PMC

Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Absence of the BRAF mutation in HBME1+ and CK19+ atypical cell clusters in Hashimoto thyroiditis: supportive evidence against preneoplastic change. Am J Clin Pathol. 2009;132(6):906–912. doi: 10.1309/AJCPCGCZZ1OYF0IC. PubMed DOI

Chui MH, Cassol CA, Asa SL, Mete O. Follicular epithelial dysplasia of the thyroid: morphological and immunohistochemical characterization of a putative preneoplastic lesion to papillary thyroid carcinoma in chronic lymphocytic thyroiditis. Virchows Arch. 2013;462(5):557–563. doi: 10.1007/s00428-013-1397-1. PubMed DOI

Lintusaari J, Vesaniemi E, Kalfert D, Ilvesaro J, Ludvikova M, Kholova I. IgG4-positive plasma cells in Hashimoto thyroiditis: IgG4-related disease or inflammation-related IgG4-positivity? APMIS. 2020;128(9):531–538. doi: 10.1111/apm.13067. PubMed DOI

Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria and Explanatory Notes. 1. New York, USA: Springer; 2010.

Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology. 2. Cham, Switzerland: Springer; 2018.

Cochand-Priollet B, Dahan H, Laloi-Michelin M, Polivka M, Saada M, Herman P, Guillausseau PJ, Hamzi L, Pote N, Sarfati E, Wassef M, Combe H, Raulic-Raimond D, Chedin P, Medeau V, Casanova D, Kania R. Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fine-needle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological control. Thyroid. 2011;21(10):1067–1073. doi: 10.1089/thy.2011.0014. PubMed DOI

Fadda G, Rossi ED, Raffaelli M, Pontecorvi A, Sioletic S, Morassi F, Lombardi CP, Zannoni GF, Rindi G. Follicular thyroid neoplasms can be classified as low- and high-risk according to HBME-1 and Galectin-3 expression on liquid-based fine-needle cytology. Eur J Endocrinol. 2011;165(3):447–453. doi: 10.1530/EJE-11-0181. PubMed DOI

Margari N, Giovannopoulos I, Pouliakis A, Mastorakis E, Gouloumi AR, Panayiotides IG, Karakitsos P. Application of Immunocytochemistry on Cell Block Sections for the Investigation of Thyroid Lesions. Acta Cytol. 2018;62(2):137–144. doi: 10.1159/000485824. PubMed DOI

Kalfert D, Ludvikova M, Kholova I, Ludvik J, Topolocan O, Plzak J. Combined use of galectin-3 and thyroid peroxidase improves the differential diagnosis of thyroid tumors. Neoplasma. 2020;67(1):164–170. doi: 10.4149/neo_2019_190128N86. PubMed DOI

Ma H, Yan J, Zhang C, Qin S, Qin L, Liu L, Wang X, Li N. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis. Int J Clin Exp Pathol. 2014;7(11):7999–8007. PubMed PMC

Prasad ML, Huang Y, Pellegata NS, de la Chapelle A, Kloos RT. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology. 2004;45(1):39–46. doi: 10.1111/j.1365-2559.2004.01876.x. PubMed DOI

Rhoden KJ, Unger K, Salvatore G, Yilmaz Y, Vovk V, Chiappetta G, Qumsiyeh MB, Rothstein JL, Fusco A, Santoro M, Zitzelsberger H, Tallini G. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab. 2006;91(6):2414–2423. doi: 10.1210/jc.2006-0240. PubMed DOI

Weetman AP. Cellular immune responses in autoimmune thyroid disease. Clin Endocrinol (Oxf) 2004;61(4):405–413. doi: 10.1111/j.1365-2265.2004.02085.x. PubMed DOI

Asioli S, Erickson LA, Lloyd RV. Solid cell nests in Hashimoto's thyroiditis sharing features with papillary thyroid microcarcinoma. Endocr Pathol. 2009;20(4):197–203. doi: 10.1007/s12022-009-9095-x. PubMed DOI

Kholová I, Schalin-Jäntti C (2018) Thyroid fine needle aspiration cytology. In: Huhtaniemi I, Martini L (eds) Encyclopedia of Endocrine Diseases, vol 4. 2nd edn. Elsevier, Amsterdam, Netherlands, pp 565–572

Mete O, Asa SL. Pitfalls in the diagnosis of follicular epithelial proliferations of the thyroid. Adv Anat Pathol. 2012;19(6):363–373. doi: 10.1097/PAP.0b013e318271a5ac. PubMed DOI

Mete O, Asa SL. Oncocytes, oxyphils, Hurthle, and Askanazy cells: morphological and molecular features of oncocytic thyroid nodules. Endocr Pathol. 2010;21(1):16–24. doi: 10.1007/s12022-009-9102-2. PubMed DOI

Harvey AM, Truong LD, Mody DR. Diagnostic pitfalls of Hashimoto's/lymphocytic thyroiditis on fine-needle aspirations and strategies to avoid overdiagnosis. Acta Cytol. 2012;56(4):352–360. doi: 10.1159/000338738. PubMed DOI

Jing X, Michael CW. Potential pitfalls for false suspicion of papillary thyroid carcinoma: a cytohistologic review of 22 cases. Diagn Cytopathol. 2012;40(Suppl 1):E74–79. doi: 10.1002/dc.21726. PubMed DOI

Kholova I, Ludvikova M. Thyroid atypia of undetermined significance or follicular lesion of undetermined significance: an indispensable Bethesda 2010 diagnostic category or waste garbage? Acta Cytol. 2014;58(4):319–329. doi: 10.1159/000366498. PubMed DOI

PD-L1 and PD-1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor